NewAmsterdam Pharma Company N.V. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenue of $19.1 million for the three months ended June 30, 2025, a substantial increase of 740% compared to $2.3 million in the same period last year. This growth was primarily attributed to the recognition of $16.1 million in revenue related to the second installment of development cost contributions under its licensing agreement with Menarini. For the first half of 2025, total revenue reached $22.1 million, up from $3.7 million in the prior year.
Despite the increase in revenue, NewAmsterdam Pharma reported an operating loss of $35.6 million for the second quarter, an improvement from a loss of $52.6 million in the same quarter of 2024. The company’s total operating expenses remained relatively stable at $54.8 million, slightly down from $54.9 million year-over-year. Research and development expenses decreased by 28% to $27.5 million, reflecting the completion of several Phase 3 clinical trials. However, selling, general, and administrative expenses rose by 65% to $27.3 million, driven by increased personnel costs and marketing expenses as the company prepares for potential commercialization of its lead product, obicetrapib.
Operationally, NewAmsterdam Pharma has made strides in its clinical development programs. The company is focused on obicetrapib, a CETP inhibitor aimed at lowering LDL-C levels in patients with cardiovascular disease. The company has completed multiple Phase 3 trials, with positive results indicating significant LDL-C reductions. As of June 30, 2025, the company had 112,628,458 ordinary shares outstanding, reflecting its ongoing capital-raising efforts, including the issuance of shares and warrants.
Looking ahead, NewAmsterdam Pharma remains optimistic about its future prospects. The company plans to continue its clinical trials and is preparing for potential regulatory submissions for obicetrapib. The partnership with Menarini is expected to play a crucial role in the commercialization of the product in Europe, while the company aims to pursue development and commercialization in the United States independently. The company’s cash and cash equivalents, totaling $563.9 million as of June 30, 2025, provide a solid financial foundation to support its ongoing operations and strategic initiatives.
About NewAmsterdam Pharma Co N.V.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.